China Pharma Holdings, Inc. to Present at Two Upcoming U.S. Investor Conferences
President and CEO, Ms. Zhilin Li, and CFO, Mr. Xinhua Wu, will attend andare available for one-on-one meetings during both conferences to highlightChina Pharma Holding's current product portfolio, development pipeline,research and development platform, recent financial highlights and growthstrategy.
Ms. Li commented, "I am delighted to visit the US and meet with investorsand analysts. I consider these conferences a great opportunity to listen totheir ideas, develop mutual understanding, and raise China Pharma's profile inthe US. Our goal of this trip is to better understand the US capital marketsin order to improve our communications and performance for shareholders."
A live audio webcast of China Pharma Holding's presentation at RothCapital's conference will be available athttp://www.wsw.com/webcast/roth18/cphi.ob and accessible for 90 days followingthe presentation. Please log on 15 minutes prior to the presentation todownload any necessary materials.
For more information on Roth Capital's "China Comes to Vegas" Conference,dedicated to Chinese-based, U.S. listed companies, please visithttp://www.roth.com .
For more information on Rodman & Renshaw's Annual Global InvestmentConference, featuring Steel, Metals & Mining, Energy, Healthcare, Asia &Growth and SPACs Tracks, please visithttp://www.rodmanandrenshaw.com/conferences .
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a biopharmaceutical company with rapidlygrowing profit that develops, manufactures, and markets treatments for a widerange of high incidence and high mortality conditions in China, includingcardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supportedby 8 scalable GMP-certified product lines covering the major dosage forms. Inaddition, the Company has a broad and expanding distribution network acrossmore than 29 provinces, municipalities and autonomous regions. The Company isregistered in Delaware, USA. Hainan Helpson Bio-pharmaceutical Co., Ltd(Helpson), located in Haikou City, Hainan Province, China, is a wholly ownedsubsidiary of China Pharma Holdings, Inc. For more information about ChinaPharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement
Certain statements in this press release and oral statements made by ChinaPharma on its conference call in relation to this release, constituteforward-looking statements for purposes of the safe harbor provisions underThe Private Securities Litigation Reform Act of 1995. Any statements set forthabove that are not historical facts are forward-looking statements thatinvolve risks and uncertainties that could cause actual results to differmaterially from those in the forward-looking statements, which may include,but are not limited to, such factors as unanticipated changes in productdemand, increased competition, failure to obtain or maintain intellectualproperty protection, downturns in the Chinese economy, uncompetitive levels ofresearch and development, failure to obtain regulatory approvals, and otherinformation detailed from time to time in the Company's filings and futurefilings with the United States Securities and Exchange Commission. Theforward-looking statements made herein speak only as of the date of this pressrelease and the Company undertakes no duty to update any forward-lookingstatement to conform the statement to actual results or changes in thecompany's expectations.-- Rodman and Renshaw's Annual Global Investment Conference (Asia and Growth Track) will be held November 10-12, 2008 at the New York Palace Hotel in New York City, New York. The Company's presentation will take place on Monday, November 10th at 5:20pm ET in Henry Salon (5th Floor). -- Roth Capital's "China Comes to Vegas" conference will be held November 19-21, 2008 at the Wynn Hotel in Las Vegas, Nevada. The Company's presentation will take place on Friday, November 21st at 9:30am ET in Palmer 2 - Track 2.
SOURCE China Pharma Holdings, Inc.
You May Also Like